List of Excipients in Branded Drug LYLEQ

Generic Drugs Containing LYLEQ

Company	Ingredient	NDC	Excipient
Afaxys Pharma LLC	norethindrone	50102-300	D&C YELLOW NO. 10
Afaxys Pharma LLC	norethindrone	50102-300	FD&C YELLOW NO. 6
Afaxys Pharma LLC	norethindrone	50102-300	LACTOSE MONOHYDRATE
Afaxys Pharma LLC	norethindrone	50102-300	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LYLEQ?

# Of NDCs	Excipient
2	D&C YELLOW NO. 10
2	FD&C YELLOW NO. 6
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE

Lyleq Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Lyleq is a 0.35 mg norethindrone progestin-only oral contraceptive marketed by Lupin Pharmaceuticals. Its core excipient platform is a conventional immediate-release tablet based on lactose monohydrate, corn starch, and magnesium stearate. The strongest commercial opportunities are differentiated generic formulations, excipient substitution for patients with sensitivities, contract manufacturing, improved dose uniformity, and packaging or adherence solutions rather than novel-drug exclusivity.

What is Lyleq and how is it regulated?

Lyleq contains norethindrone, a synthetic progestin used for contraception. Each tablet contains 0.35 mg of norethindrone, and the product is supplied as a 28-tablet regimen with continuous dosing and no inert tablet interval. The FDA labeling identifies Lyleq as an oral tablet for prescription contraception.[1]

Lyleq product profile

Attribute	Lyleq
Active ingredient	Norethindrone
Strength	0.35 mg per tablet
Dosage form	Immediate-release oral tablet
Therapeutic class	Progestin-only contraceptive
Dosing	One tablet daily at the same time
Pack configuration	28 tablets
Marketing company	Lupin Pharmaceuticals
FDA pathway	Prescription oral contraceptive product
Biosimilar relevance	None; Lyleq is a small-molecule product
Primary formulation challenge	Uniform distribution of a very low drug load

Norethindrone has been used in oral contraceptives for decades. The commercial value of Lyleq therefore depends mainly on manufacturing scale, product reliability, supply continuity, payer access, brand recognition, and formulation differentiation.

What excipients are used in Lyleq tablets?

Lyleq uses a conventional solid-dose excipient system. The FDA label identifies lactose monohydrate, corn starch, and magnesium stearate as inactive ingredients.[1]

Lyleq excipient functions

Excipient	Primary function	Commercial and technical relevance
Lactose monohydrate	Diluent and tablet-volume builder	Supports manufacturability for a 0.35 mg active dose
Corn starch	Disintegrant and filler	Promotes tablet breakup and helps manage low-dose blend behavior
Magnesium stearate	Lubricant	Reduces sticking and ejection force during compression

The formulation is technically simple, but the low norethindrone dose creates a high content-uniformity burden. The active ingredient represents a small fraction of total tablet mass. Manufacturing controls must therefore manage segregation, blend uniformity, sampling error, lubrication time, and compression-force variation.

Why the low dose matters

A 0.35 mg dose increases the importance of:

• Premixing and geometric dilution.
• Controlled particle-size distribution.
• Low-segregation excipient grades.
• Short, validated lubrication cycles.
• Blend uniformity testing.
• In-process weight and hardness controls.
• Stability testing for potency and degradation products.

The most valuable excipient improvements may not be novel ingredients. They may be higher-functionality grades that improve powder flow, reduce segregation, or increase content-uniformity robustness without changing the approved dosage form.

Which excipient strategies could differentiate Lyleq?

Lactose-free Lyleq alternative

Replacing lactose with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler could create a lactose-free product. The commercial rationale would be patient preference, intolerance concerns, or broader pharmacy substitution flexibility.

A lactose-free formulation would require evaluation of:

• Norethindrone distribution in the blend.
• Tablet tensile strength.
• Disintegration and dissolution.
• Moisture sensitivity.
• Long-term and accelerated stability.
• Bioequivalence against the reference product.

Lactose-free positioning may have greater value in direct-to-consumer channels and specialty pharmacy than in highly commoditized retail generic channels, where price and formulary status dominate.

Corn-starch-free formulation

Corn starch can be replaced with alternatives such as sodium starch glycolate, crospovidone, or croscarmellose sodium. The choice would depend on dissolution performance, tablet robustness, and supplier economics.

A modern superdisintegrant system could support:

• Faster disintegration.
• Lower tablet weight.
• Improved manufacturability on high-speed presses.
• Greater flexibility in film coating.
• Potentially better performance after exposure to humidity.

Any change must preserve immediate-release behavior. Faster disintegration alone does not create a clinically meaningful advantage unless it improves manufacturing consistency, patient handling, or regulatory comparability.

Magnesium-stearate alternatives

Magnesium stearate is effective but can create over-lubrication risks, including reduced tablet tensile strength and slower dissolution. Alternatives include sodium stearyl fumarate or other low-hydrophobicity lubricants.

A substitute may be commercially attractive if it:

• Reduces dissolution variability.
• Allows a wider lubrication-process window.
• Improves tablet ejection.
• Supports continuous manufacturing.
• Reduces sensitivity to lubricant blending time.

The principal risk is that lubricant substitution can alter dissolution and bioequivalence. The benefit must be demonstrated through comparative release testing and manufacturing validation.

Direct-compression platform

A direct-compression formulation using engineered lactose, spray-dried mannitol, microcrystalline cellulose, or co-processed excipients could reduce granulation steps and manufacturing cost. The strategy is most compelling if the selected excipient delivers both flow and content-uniformity benefits.

For Lyleq, direct compression has to address:

• Low-dose active distribution.
• Norethindrone particle-size variability.
• Blend segregation during transfer.
• Tablet weight variation.
• Punch adhesion and ejection.
• Scale-up from development equipment to commercial presses.

A wet-granulated process could improve uniformity but may add processing complexity and increase exposure to water, heat, or prolonged drying. The optimal approach depends on the active-material particle characteristics and validated process capability.

What formulations are protected by Lyleq patents?

Public product information identifies the Lyleq formulation as an immediate-release norethindrone tablet. The FDA label does not disclose a formulation patent or provide a proprietary excipient platform.[1]

Patent and exclusivity assessment

Issue	Assessment
Active ingredient patent	Norethindrone is an established active ingredient with no meaningful composition-of-matter exclusivity for Lyleq
Excipient patent	No proprietary Lyleq excipient system is identified in the product label
Formulation patent	No specific Lyleq formulation patent is identified in the cited FDA labeling
Method-of-use patent	The contraceptive use is established and generally offers limited differentiation
Biosimilar exclusivity	Not applicable
Regulatory exclusivity	Depends on the specific FDA approval basis and current Orange Book records
Patent expiry date	No Lyleq-specific patent expiry date is established by the cited product label

A current Orange Book review is necessary for a definitive listing determination because patent listings, delistings, and regulatory exclusivity records can change. The absence of a patent statement in labeling does not by itself establish that no Orange Book-listed patent exists.

What is the Orange Book status of Lyleq?

Lyleq is a small-molecule oral drug and is evaluated through the FDA drug approval framework rather than the biosimilar pathway. Orange Book analysis should focus on:

• The product’s NDA or application number.
• Listed patents, if any.
• Patent use codes.
• Pediatric exclusivity.
• Three-year clinical-investigation exclusivity, if granted.
• Whether the product is eligible for ANDA referencing.
• Any certified Paragraph IV challenges.

The commercial risk from abbreviated new drug applications is structurally higher for a low-complexity immediate-release tablet than for an injectable, modified-release product, or complex drug-device combination. A competitor can potentially replicate the dosage form without overcoming a specialized delivery platform.

When does Lyleq lose exclusivity?

Lyleq does not have the profile of a new chemical entity with a long period of composition-of-matter protection. The practical exclusivity timeline depends on the FDA approval basis and any listed patents or regulatory exclusivities associated with the application.

Exclusivity scenarios

Scenario	Commercial effect
No enforceable patent or regulatory exclusivity	ANDA competition can enter once FDA approval requirements are met
Three-year exclusivity	May delay approval of an ANDA relying on certain new clinical investigations, but does not create broad product exclusivity
Listed formulation or method patent	Could delay or limit generic launch depending on certification and litigation
Paragraph IV certification	May trigger patent litigation and a potential 30-month stay
No litigation or settlement	Generic launch timing depends on FDA review, approval, and business launch decisions

The key issue is not the age of norethindrone. It is whether Lyleq has application-specific regulatory protection or listed patents that affect ANDA timing.

Which companies are challenging Lyleq?

No specific Paragraph IV challenger, ANDA litigation matter, or settlement involving Lyleq is established in the sources cited here. The competitive field includes manufacturers of norethindrone 0.35 mg tablets and the nonprescription Opill product, which contains the same progestin but is positioned through a different regulatory and commercial model.[2]

Competitive products

Product or category	Active ingredient	Key distinction
Lyleq	Norethindrone 0.35 mg	Prescription progestin-only tablet
Generic norethindrone tablets	Norethindrone 0.35 mg	Price-driven competition
Opill	Norgestrel 0.075 mg	FDA-approved nonprescription progestin-only contraceptive
Combined oral contraceptives	Estrogen plus progestin	Different safety profile and patient population
Long-acting contraceptives	Various hormones or devices	Higher duration and different adherence model

Lyleq competes most directly with prescription norethindrone tablets, not with biosimilars or complex generics. Opill expands consumer access to progestin-only contraception but does not substitute perfectly for norethindrone because it contains a different progestin and has different labeling, dosing, and market positioning.

What commercial opportunities exist for Lyleq excipients?

Excipient-supplier opportunity

Suppliers can target Lyleq-type products with high-functionality excipients that improve low-dose tablet performance. The most relevant value propositions are:

1. Better content uniformity.
2. Lower segregation risk.
3. Improved direct-compression performance.
4. Faster disintegration without excessive friability.
5. Reduced sensitivity to magnesium-stearate over-lubrication.
6. Lactose-free or corn-starch-free positioning.
7. Reliable global supply and dual sourcing.

The addressable market is broader than Lyleq itself because the same formulation requirements apply to low-dose hormonal tablets, potent cardiovascular drugs, thyroid products, and other low-dose immediate-release medicines.

Contract development and manufacturing

A CMO can offer a complete platform for progestin-only tablets, including:

• Low-dose premix development.
• Blend-uniformity optimization.
• Direct-compression scale-up.
• Film coating.
• 28-day blister packaging.
• Stability programs.
• ANDA or post-approval supplement support.
• Dual-site supply strategies.

Manufacturers with validated low-dose handling and high-containment capabilities may gain an advantage even though norethindrone is not generally regarded as a highly potent oncology compound. Hormonal APIs require disciplined occupational and environmental controls, especially during dispensing, blending, compression, and cleaning validation.

Patient-centered reformulation

Commercial differentiation could come from:

• Lactose-free tablets.
• Smaller tablets for swallowing.
• Lower-friction blister packs.
• Calendarized packaging.
• Tamper-evident unit-dose packs.
• Moisture-protective packaging.
• Color or imprint improvements that reduce medication errors.

An orally disintegrating or chewable norethindrone formulation could improve administration, but it would face greater regulatory and formulation complexity. Taste masking, dose uniformity, stability, and bioequivalence would become central development risks.

What manufacturing and intellectual-property barriers affect Lyleq?

The principal barriers are process and regulatory barriers rather than fundamental patent barriers.

Manufacturing barriers

• Achieving uniform distribution of 0.35 mg of active ingredient.
• Preventing segregation during transfer and compression.
• Maintaining dissolution after lubricant or excipient changes.
• Controlling hormonal cross-contamination.
• Establishing cleaning limits and validated analytical methods.
• Securing consistent grades of lactose, starch, or substitute excipients.
• Managing supply-chain qualification for global production.

Intellectual-property barriers

A differentiated formulation could create patentable subject matter if it demonstrates a non-obvious combination of excipients, process parameters, particle engineering, packaging, or stability performance. Generic substitution of one conventional excipient for another is unlikely to provide strong protection without unexpected technical results.

Potentially stronger claims could involve:

• A narrowly defined low-dose blend with demonstrated uniformity.
• A process that reduces segregation at commercial scale.
• A stability-enhancing formulation under specified humidity conditions.
• A formulation that achieves a defined dissolution profile without granulation.
• A packaging system that preserves potency or impurity limits.

The strongest protection would generally come from a combination of composition and process claims supported by comparative data, not from naming a routine excipient substitution alone.

What revenue exposure does Lyleq create for Lupin?

Lupin does not generally disclose Lyleq as a separately reported revenue line in its public financial reporting. Product-level revenue, gross margin, prescription volume, and market share therefore cannot be assigned reliably from the cited sources.[3]

The product’s financial exposure is likely determined by:

• Prescription volume.
• Net price after rebates.
• Generic substitution.
• Payer coverage.
• Retail versus specialty distribution.
• Competitor entry.
• Supply continuity.
• Marketing investment.

A simple immediate-release contraceptive can generate durable volume but is vulnerable to price erosion when multiple equivalent products are available. Formulation differentiation would have the greatest financial value if it supports a distinct reimbursement position or reduces manufacturing failures and supply interruptions.

How strong is the Lyleq patent estate?

The Lyleq patent estate appears limited based on the public product information reviewed. The active ingredient is old, the dosage form is conventional, and the label identifies no proprietary delivery technology. Commercial strength therefore depends more on execution than on exclusionary patent rights.

Relative strength assessment

Dimension	Assessment
Composition-of-matter protection	Weak or unavailable for this established active
Delivery-system protection	Limited; immediate-release tablet
Excipient differentiation	Possible, but requires technical evidence
Manufacturing know-how	Potentially meaningful
Regulatory switching costs	Moderate
Generic vulnerability	High relative to complex dosage forms
Biosimilar vulnerability	Not applicable
Supply-chain advantage	Potentially significant

Key Takeaways

• Lyleq is a 0.35 mg norethindrone immediate-release tablet marketed by Lupin.
• The labeled excipients are lactose monohydrate, corn starch, and magnesium stearate.
• The main technical challenge is content uniformity at a very low active dose.
• Lactose-free, corn-starch-free, direct-compression, and improved-lubrication formulations are the clearest excipient opportunities.
• No Lyleq-specific formulation patent, Paragraph IV challenge, litigation matter, or settlement is established in the cited sources.
• Lyleq is not subject to biosimilar competition because norethindrone is a small-molecule drug.
• Manufacturing know-how, supply reliability, packaging, and payer access are more important commercial variables than composition-of-matter patent protection.
• Product-level Lyleq revenue is not separately disclosed in the cited Lupin reporting.

FAQs

Is Lyleq the same as Opill?

No. Lyleq contains norethindrone 0.35 mg and is a prescription product. Opill contains norgestrel 0.075 mg and is FDA-approved for nonprescription use.[1,2]

Can lactose be removed from a Lyleq generic?

Yes, a developer could pursue a lactose-free formulation, but the replacement must preserve content uniformity, dissolution, stability, tablet strength, and bioequivalence.

Is a norethindrone 0.35 mg tablet a complex generic?

Generally, no. It is an immediate-release oral tablet, although the low dose creates meaningful manufacturing and analytical challenges.

Can an excipient supplier patent a Lyleq reformulation?

Potentially. Patent strength would depend on whether the formulation or manufacturing process produces a non-obvious technical result supported by comparative data.

Does Lyleq have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Lyleq is a small-molecule oral contraceptive and would face generic, not biosimilar, competition.

References

1. U.S. Food and Drug Administration. (2024). Lyleq (norethindrone) tablets, 0.35 mg: Prescribing information. Lupin Pharmaceuticals, Inc.
2. U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
3. Lupin Limited. (2024). Annual report 2023-2024. https://www.lupin.com/investors/financial-information/annual-reports/